** Brokerage TD Cowen starts coverage on drug developer Lenz Therapeutics LENZ.O with "buy" rating and $60 PT, as it expects "high consumer satisfaction" with co's once-daily eye drop, LNZ100
** Says LNZ100 has demonstrated "best-in-class efficacy and clean safety" in treating presbyopia, a condition that affects 128 mln US adults, causing an inability to focus on near objects
** Estimates over $1 bln in peak sales for LNZ100, representing just "2% of presbyopia market"
** Says unlike competitor AbbVie's ABBV.N Vuity which has "poor tolerability/safety, with short duration of effect," LNZ100's aceclidine is "derisked for real-world safety"
** Brokerage says investors should "buy the derisked commercial story, as the launch should impress" and potentially "surprise to the upside"
** The US drug regulator is expected to decide on approval for LNZ100 in early August
** LENZ gained 131% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。